Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$10.78 -1.1%	$14.34	$6.59 ▼ $21.00	$489.60M	1.19	467,716 shs	126,987 shs
KIDS OrthoPediatrics	$20.31 +0.9%	$21.82	$19.52 ▼ $35.99	$493.15M	1.09	197,842 shs	34,393 shs
NPCE NeuroPace	$13.39 +1.6%	$12.89	$5.45 ▼ $18.98	$438.20M	2.03	161,852 shs	41,836 shs
PDEX Pro-Dex	$42.76 +3.7%	$51.81	$16.84 ▼ $70.26	$139.03M	0.37	31,196 shs	15,539 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	-4.05%	-0.55%	-34.93%	-38.66%	+58.89%
KIDS OrthoPediatrics	-1.57%	-1.57%	-4.55%	-19.87%	-35.26%
NPCE NeuroPace	-2.73%	+5.70%	+14.22%	+17.80%	+103.55%
PDEX Pro-Dex	-3.58%	-0.10%	-8.21%	+21.18%	+109.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	3.0322 of 5 stars	3.5	3.0	0.0	3.2	2.5	0.6
KIDS OrthoPediatrics	4.3779 of 5 stars	3.4	2.0	3.9	3.3	4.2	0.6
NPCE NeuroPace	2.3333 of 5 stars	2.4	3.0	0.0	2.3	4.2	0.6
PDEX Pro-Dex	3.1541 of 5 stars	3.5	2.0	0.0	2.1	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$22.20	105.90% Upside
KIDS OrthoPediatrics	2.83	Moderate Buy	$35.83	76.48% Upside
NPCE NeuroPace	2.83	Moderate Buy	$15.50	15.80% Upside
PDEX Pro-Dex	3.00	Buy	$56.00	30.95% Upside

Current Analyst Ratings Breakdown

Latest PDEX, AXGN, KIDS, and NPCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	NPCE NeuroPace	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
5/27/2025	PDEX Pro-Dex	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$54.00 ➝ $56.00
5/14/2025	NPCE NeuroPace	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $16.00
5/14/2025	NPCE NeuroPace	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$17.00 ➝ $17.00
5/13/2025	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
5/8/2025	KIDS OrthoPediatrics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $30.00
5/8/2025	KIDS OrthoPediatrics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/11/2025	KIDS OrthoPediatrics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$26.00 ➝ $24.00
4/9/2025	KIDS OrthoPediatrics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	KIDS OrthoPediatrics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
3/17/2025	AXGN AxoGen	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$194.52M	2.52	N/A	N/A	$2.22 per share	4.86
KIDS OrthoPediatrics	$212.45M	2.32	N/A	N/A	$16.14 per share	1.26
NPCE NeuroPace	$84.31M	5.21	N/A	N/A	$0.79 per share	16.94
PDEX Pro-Dex	$64.12M	2.17	$1.23 per share	34.81	$9.76 per share	4.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$21.72M	-$0.15	N/A	N/A	N/A	-7.91%	-14.91%	-7.49%	8/14/2025 (Estimated)
KIDS OrthoPediatrics	-$20.97M	-$1.75	N/A	N/A	N/A	-15.00%	-5.78%	-4.80%	8/4/2025 (Estimated)
NPCE NeuroPace	-$32.96M	-$0.84	N/A	N/A	N/A	-36.74%	-205.41%	-28.29%	8/12/2025 (Estimated)
PDEX Pro-Dex	$2.13M	$2.80	21.21	20.76	N/A	11.06%	21.68%	12.40%	N/A

Latest PDEX, AXGN, KIDS, and NPCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	NPCE NeuroPace	-$0.26	-$0.21	+$0.05	-$0.21	$21.85 million	$22.52 million
5/7/2025	Q1 2025	KIDS OrthoPediatrics	-$0.26	-$0.39	-$0.13	-$0.46	$51.68 million	$52.41 million
5/1/2025	Q3 2025	PDEX Pro-Dex	$0.47	$0.98	+$0.51	$0.98	$17.70 million	$17.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
KIDS OrthoPediatrics	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A
PDEX Pro-Dex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.67	3.74	2.47
KIDS OrthoPediatrics	0.19	7.17	3.68
NPCE NeuroPace	6.03	5.59	4.77
PDEX Pro-Dex	0.33	2.58	1.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
KIDS OrthoPediatrics	69.05%
NPCE NeuroPace	78.83%
PDEX Pro-Dex	15.28%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
KIDS OrthoPediatrics	32.70%
NPCE NeuroPace	22.20%
PDEX Pro-Dex	47.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	45.54 million	40.93 million	Optionable
KIDS OrthoPediatrics	200	24.29 million	16.52 million	Optionable
NPCE NeuroPace	170	32.80 million	23.22 million	Optionable
PDEX Pro-Dex	140	3.26 million	1.71 million	Not Optionable

PDEX, AXGN, KIDS, and NPCE Headlines

Recent News About These Companies

Financial Survey: InspireMD (NYSE:NSPR) vs. Pro-Dex (NASDAQ:PDEX)

June 5 at 2:07 AM | americanbankingnews.com

Pro-Dex (NASDAQ:PDEX) Price Target Raised to $56.00 at Ascendiant Capital Markets

May 28, 2025 | marketbeat.com

Ascendiant Capital Markets Issues Positive Forecast for Pro-Dex (NASDAQ:PDEX) Stock Price

May 28, 2025 | americanbankingnews.com

OMERS ADMINISTRATION Corp Takes Position in Pro-Dex, Inc. (NASDAQ:PDEX)

May 22, 2025 | marketbeat.com

Are Pro-Dex, Inc.'s (NASDAQ:PDEX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

May 20, 2025 | finance.yahoo.com

Pro-Dex (NASDAQ:PDEX) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?

May 15, 2025 | marketbeat.com

9,260 Shares in Pro-Dex, Inc. (NASDAQ:PDEX) Bought by Marshall Wace LLP

May 6, 2025 | marketbeat.com

Pro-Dex: Crash After Strong Earnings Leads To A Buying Opportunity

May 5, 2025 | seekingalpha.com

Here's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of Investors

May 4, 2025 | uk.finance.yahoo.com

Pro-Dex, Inc. (PDEX) Q3 Earnings Surpass Estimates

May 1, 2025 | zacks.com

Pro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month Results

May 1, 2025 | accessnewswire.com

ProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?

April 25, 2025 | zacks.com

Take the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in Focus

April 21, 2025 | zacks.com

ProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?

April 3, 2025 | zacks.com

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 842 Shares

April 2, 2025 | insidertrades.com

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 836 Shares

April 1, 2025 | insidertrades.com

Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 3,096 Shares of Stock

March 28, 2025 | insidertrades.com

Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 5,151 Shares of Stock

March 18, 2025 | insidertrades.com

With 38% ownership in Pro-Dex, Inc. (NASDAQ:PDEX), hedge funds investors have a lot riding on the business

March 11, 2025 | finance.yahoo.com

ProDex (PDEX) Upgraded to Strong Buy: Here's What You Should Know

February 28, 2025 | zacks.com

(PDEX) Investment Report

February 8, 2025 | news.stocktradersdaily.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDEX, AXGN, KIDS, and NPCE Company Descriptions

AxoGen NASDAQ:AXGN

$10.78 -0.12 (-1.08%)

As of 11:58 AM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

OrthoPediatrics NASDAQ:KIDS

$20.30 +0.19 (+0.92%)

As of 11:57 AM Eastern

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

NeuroPace NASDAQ:NPCE

$13.40 +0.23 (+1.75%)

As of 11:57 AM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Pro-Dex NASDAQ:PDEX

$42.76 +1.51 (+3.67%)

As of 11:58 AM Eastern

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time